# US 2021/0340562 A1 · Engineered long interspersed element (line) transposons and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340562 A1
- Document ID: US20210340562A1
- Status: Published application
- Kind: A1
- Application number: 17/286,772
- Filed: 2019-10-21
- Published: 2021-11-04
- Earliest claimed: 2018-10-19
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Shawn Christensen
- Web page: https://patentgrep.com/patent/US20210340562A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/85: for animal cells
- C07K 14/43586: {from silkworms}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12N 2800/90: Vectors containing a transposable element
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Engineered transposons and methods of use thereof are provided. The transposons typically include an RNA component and a protein component. The RNA component can include, for example, a DNA targeting sequence, one or more protein binding motifs, and a nucleic acid sequence of interest to be integrated into a target DNA. The protein component is typically derived from a RLE LINE element protein and can include a DNA binding domain, an RNA binding domain, a reverse transcriptase, a linker domain, and an endonuclease. Pharmaceutical compositions and methods of use for introducing nucleic acid sequences into the genomes of cells are also provided.

## Claims

### Claim 1

A RNA component comprising a DNA targeting sequence, one or more protein binding motifs (PBM), and a nucleic acid sequence of interest to be integrated into a DNA target site, wherein the DNA targeting sequence, the protein binding motifs, and sequence of interest are operably linked such that they can bind to a protein component derived from a parental Long Interspersed (LINE) element protein and be reverse transcribed into cDNA and the cDNA can be integrated into the DNA at the DNA target site.

### Claim 2 (depends on 1)

The RNA component of claim 1, wherein the protein component comprises one or more of an RNA binding domain, a linker domain, a reverse transcriptase, a DNA endonuclease, and wherein the one or more protein binding motifs bind the RNA component to the RNA binding domain, linker domain, reverse transcriptase, DNA endonuclease, or a combination thereof of the protein component.

### Claim 3 (depends on 1)

The RNA component of claim 1, wherein the RNA component comprises elements from or derived from a parental LINE or SINE backbone and the nucleic acid sequence of interest of RNA component is heterologous to the LINE or SINE; wherein protein component comprises elements from or derived from a parental LINE; or a combination thereof, and/or (a) the DNA targeting sequence is heterologous to the parental LINE or SINE; and/or (b) the sequence of interest encodes a gene, a fragment of a gene, or a functional nucleic acid.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The RNA component of claim 1, comprising: (a) the 3′ PBM sequence from or derived from a parental LINE or SINE element; and/or (b) a CRISPR/Cas tracer sequence, a CRISPR/Cas guide sequence, or a combination thereof; and/or (c) a 5′ PBM sequence from or derived from the parental LINE or SINE element; and/or (d) a ribozyme.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 6)

The RNA component of claim 6, wherein: (a) the 5′ PBM comprises a non-functional IRES sequence; (b) the ribozyme is Hepatitis Delta Virus like ribozyme; and/or (c) the RLE LINE is an R2 LINE.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 2)

The RNA component of claim 2, wherein the parental LINE or SINE is a Restriction-like endonuclease (RLE) LINE.

### Claim 13

(canceled)

### Claim 14 (depends on 3)

The RNA component of claim 3, wherein the parental LINE or SINE backbone of the RNA component and the parental LINE backbone of the protein component are the same LINE and/or the SINE is derived from or an ancestor of the LINE.

### Claim 15

A protein component comprising a DNA binding domain, an RNA binding domain, a reverse transcriptase, a linker domain, and an endonuclease wherein the DNA binding domain, RNA binding domain, reverse transcriptase, linker domain, and endonuclease are operably linked such that they can bind to an RNA component and DNA at a DNA target site, and facilitate reverse transcription of the RNA component into cDNA, and integration of the cDNA into the DNA at the DNA target site.

### Claim 16 (depends on 15)

The protein component of claim 15, wherein the RNA component comprises a DNA targeting sequence, one or more protein binding motifs, and a nucleic acid sequence of interest to be integrated into the DNA target site; and/or (b) the RNA component comprises elements from or derived from a parental LINE or SINE backbone and the nucleic acid sequence of interest of RNA component is heterologous to the LINE or SINE; wherein protein component comprises elements from or derived from a parental LINE; or a combination thereof; and/or the DNA binding domain is mutated relative to the parental LINE DNA binding domain; and/or
(c) the DNA binding domain is substituted with an alternative DNA binding domain relative to the parental LINE DNA binding domain; and/or
(d) the DNA binding domain is substituted with an alternative DNA binding domain relative to the parental LINE DNA binding domain.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 16)

The protein component of claim 16, wherein: (a) the DNA binding domain is a DNA binding domain from another DNA binding protein; (b) the DNA binding domain comprises one or more of a helix-turn-helix, zinc finger, leucine zipper, winged helix, winged helix-turn-helix, helix-loop-helix, HMG-box, Wor3 domain, OB-fold domain, immunoglobulin fold, B3 domain, TAL effector, or RNA-guided domain; (c) the parental LINE or SINE is a Restriction-like endonuclease (RLE) LINE; or (d) the parental LINE or SINE backbone of the RNA component and the parental LINE backbone of the protein component are the same LINE and/or the SINE is derived from or an ancestor of the LINE.

### Claim 21

(canceled)

### Claim 22 (depends on 15)

The protein component of claim 15 wherein the sequences of one or more of the RNA binding domain, reverse transcriptase, linker domain, and endonuclease are the same as those of the parental LINE element protein, or mutated to improve binding or enzymatic activity for the RNA component relative to the parental LINE element protein.

### Claim 23

(canceled)

### Claim 24 (depends on 20)

The protein component of claim 20, wherein the RLE LINE is an R2 LINE.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A vector encoding the RNA component of claim 1.

### Claim 27 (depends on 15)

A vector encoding the protein component of claim 15.

### Claim 28 (depends on 1)

An engineered transposon comprising the RNA component of claim 1.

### Claim 29 (depends on 28)

The transposon of claim 28, wherein a productive 4-way junction is formed during the integration reaction at the DNA target site.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising the RNA component of claim 1.

### Claim 31 (depends on 1)

A method of introducing a nucleic acid sequence of interest into the genome of a cell or cells comprising contacting the cell or cells with the RNA component of claim 1.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cells are contacted in vitro; wherein the cells are contacted in vivo; or expression of the nucleic acid sequence of interest in the cells improves a one or more symptoms of a disease or disorder, or a molecular pathway underlying a disease or disorder.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cells are subsequently introduced into a subject and optionally, wherein an effective number of cells are modified to treat a subject in need thereof.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)
